Hypercalcemia and "primary" hyperparathyroidism during lithium therapy

American Journal of Psychiatry

Volumn 172, Issue 1, 2015, Pages 12-15

  Shapiro, Howard I ^a   Davis, Karina A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; HALOPERIDOL; LITHIUM; OLANZAPINE; PARATHYROID HORMONE; RISPERIDONE; VALPROATE SEMISODIUM; TRANQUILIZER;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HYPERCALCEMIA; LITHIUM BLOOD LEVEL; MALE; MANIA; PRIMARY HYPERPARATHYROIDISM; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; CHEMICALLY INDUCED; HYPERPARATHYROIDISM; PSYCHOTIC DISORDERS;

AGED; ANTIMANIC AGENTS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; LITHIUM; MALE; PSYCHOTIC DISORDERS;

EID: 84920121321     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.13081057     Document Type: Article

References (23)

1. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR: Lithium toxicity profile: a systematic review and metaanalysis. Lancet 2012; 379:721-728
2. Albert U, De Cori D, Aguglia A, Barbaro F, Lanfranco F, Bogetto F, Maina G: Lithium-associated hyperparathyroidism and hypercalcaemia: a case-control cross-sectional study. J Affect Disord 2013; 151:786-790
3. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, Adams AL: Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013; 98:1122-1129
4. Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, Beaulieu S, Yatham LN, Berk M; International Society for Bipolar Disorders: The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11:559-595
5. Miller PD, Dubovsky SL, Schrier RW, McDonald KM, Arnaud C: Hypocalciuric effect of lithium in man. Adv Exp Med Biol 1977; 81: 157-172
6. McHenry CR, Lee K: Lithium therapy and disorders of the parathyroid glands. Endocr Pract 1996; 2:103-109
7. Khandwala HM, Van Uum S: Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006; 12:54-58
8. Seely EW, Moore TJ, LeBoff MS, Brown EM: A single dose of lithium carbonate acutely elevates intact parathyroid hormone levels in humans. Acta Endocrinol (Copenh) 1989; 121:174-176
9. Lehmann SW, Lee J: Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? J Affect Disord 2013; 146:151-157
10. Mallette LE, Eichhorn E: Effects of lithium carbonate on human calcium metabolism. Arch Intern Med 1986; 146:770-776
11. Szalat A, Mazeh H, Freund HR: Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol 2009; 160:317-323
12. Awad SS, Miskulin J, Thompson N: Parathyroid adenomas versus four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg 2003; 27:486-488
13. Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S: Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 1989; 68:654-660
14. Broome JT, Solorzano CC: Lithium use and primary hyperparathyroidism. Endocr Pract 2011; 17(suppl 1):31-35
15. Rizwan MM, Perrier ND: Long-term lithium therapy leading to hyperparathyroidism: a case report. Perspect Psychiatr Care 2009; 45:62-65
16. Shlapack MA, Rizvi AA: Normocalcemic primary hyperparathyroidism: characteristics and clinical significance of an emerging entity. Am J Med Sci 2012; 343:163-166
17. Perrier ND: Asymptomatic hyperparathyroidism: a medical misnomer? Surgery 2005; 137:127-131
18. Bilezikian JP, Khan AA, Potts JTJ Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94:335-339
19. Stancer HC, Forbath N: Hyperparathyroidism, hypothyroidism, and impaired renal function after 10 to 20 years of lithium treatment. Arch Intern Med 1989; 149:1042-1045
20. Nordenström J, Elvius M, Bågedahl-Strindlund M, Zhao B, Törring O: Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism 1994; 43:1563-1567
21. Zamani A, Omrani GR, Nasab MM: Lithium's effect on bone mineral density. Bone 2009; 44:331-334
22. Cavanagh J, Smyth R, Goodwin GM: Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004; 109:91-95
23. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D: Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 2011; 96:E9-E18